ResMed (RMD)
(Delayed Data from NYSE)
$203.15 USD
-0.73 (-0.36%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $203.00 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
RMD 203.15 -0.73(-0.36%)
Will RMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RMD
Here's Why ResMed (RMD) is a Strong Growth Stock
Here's Why ResMed (RMD) is a Strong Growth Stock
RMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Hold STERIS (STE) Stock Now? Here's What to Consider
Charles River (CRL) Could be an Apt Pick Right Now: Here's Why
Here's Why Staying Invested in Neogen (NEOG) Could be Beneficial
Other News for RMD
How To YieldBoost ResMed To 18.3% Using Options
Orthofix appoints Stephanie Walsh as chief human resources officer
ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
10 Health Care Stocks Whale Activity In Today's Session
ResMed cut at Oppenheimer after Eli Lilly’s tirzepatide sleep apnea data